ideasIdea
A public fund and label pathway to trial generic drugs against cancer
Cheap old drugs such as aspirin, statins, metformin and beta-blockers show hints of cancer benefit but no company will pay for the trials. Create a public fund and a way to update their labels.
Repurposing candidates with plausible mechanisms and observational signals rarely reach definitive trials because generic status removes the commercial incentive; the aspirin adjuvant trials (ADD-ASPIRIN) are a rare exception. The proposal is a dedicated public fund for pragmatic, registry-embedded randomised trials of generics in defined cancer indications, coupled with a regulatory pathway allowing third parties (academic groups, health systems) to obtain label updates, and payer commitments to reimburse on positive results.
Hypothesis
The fund completes at least ten definitive repurposing trials in a decade and delivers at least two new indications with population-level mortality impact at negligible drug cost.
Rationale
The candidate list is long, the drugs are safe and cheap, and pragmatic trial designs make each question affordable; the missing element is an owner with an incentive.
What would test it
Fund five trials in the first tranche (for example beta-blockers in early breast cancer, statins in high-risk prostate cancer, metformin in specific contexts) with pre-registered designs and registry follow-up.
Maturity
early clinical
Who has to act
policy
Cost to try
Large (over $50M)
Years to first evidence
6
Bottlenecks it attacks
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.